Maravai LifeSciences Holdings, Inc. (MRVI) stock
MRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30170% above fair value
$7.28−0.12 (-1.62%)
Close on Nov 17, 2026Market cap $1.89BP/E –Yield –
Maravai LifeSciences total assets
Total assets on the balance sheet at the end of each period.
Maravai LifeSciences's total assets was $603.75M at Jun 30, 2026. For fiscal 2025 it was $770.58M, down 23.6% from the year before. The highest annual figure on record is $2.28B in fiscal 2022.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $770.58M | -23.6% |
| FY2024 | Dec 31, 2024 | $1.01B | -32.2% |
| FY2023 | Dec 31, 2023 | $1.49B | -34.8% |
| FY2022 | Dec 31, 2022 | $2.28B | +19.0% |
| FY2021 | Dec 31, 2021 | $1.92B | +51.0% |
| FY2020 | Dec 31, 2020 | $1.27B | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $603.75M | -32.7% |
| Q1 FY2026 | Mar 31, 2026 | $713.22M | -25.7% |
| Q4 FY2025 | Dec 31, 2025 | $770.58M | -23.6% |
| Q3 FY2025 | Sep 30, 2025 | $849.19M | -33.6% |
| Q2 FY2025 | Jun 30, 2025 | $896.97M | -37.9% |
| Q1 FY2025 | Mar 31, 2025 | $959.75M | -33.6% |
| Q4 FY2024 | Dec 31, 2024 | $1.01B | -32.2% |
| Q3 FY2024 | Sep 30, 2024 | $1.28B | -43.6% |
| Q2 FY2024 | Jun 30, 2024 | $1.44B | -36.2% |
| Q1 FY2024 | Mar 31, 2024 | $1.44B | -37.6% |
| Q4 FY2023 | Dec 31, 2023 | $1.49B | -34.8% |
| Q3 FY2023 | Sep 30, 2023 | $2.27B | +0.8% |
| Q2 FY2023 | Jun 30, 2023 | $2.26B | +4.3% |
| Q1 FY2023 | Mar 31, 2023 | $2.32B | +13.3% |
| Q4 FY2022 | Dec 31, 2022 | $2.28B | +19.0% |
| Q3 FY2022 | Sep 30, 2022 | $2.25B | +18.7% |
| Q2 FY2022 | Jun 30, 2022 | $2.17B | +35.6% |
| Q1 FY2022 | Mar 31, 2022 | $2.04B | +51.2% |
| Q4 FY2021 | Dec 31, 2021 | $1.92B | +51.0% |
| Q3 FY2021 | Sep 30, 2021 | $1.89B | – |
| Q2 FY2021 | Jun 30, 2021 | $1.60B | – |
| Q1 FY2021 | Mar 31, 2021 | $1.35B | – |
| Q4 FY2020 | Dec 31, 2020 | $1.27B | – |
See a number that looks wrong?